BACKGROUND/ OBJECTIVES: Age-related changes in blood coagulation and fibrinolysis are associated with increased risk of thrombotic events. Inherited deficiencies of coagulation proteins, such as factor V (FV) Leiden and prothrombin G20210A, explain a small fraction of venous thromboembolic disease (VTE). Additional genetic factors are likely to underlie the etiology of VTE, some of which may become manifest at older ages. METHODS: We tested 290 common SNPs within 51 thrombosis and inflammation genes for association with VTE in the Cardiovascular Health Study, a large, prospective cohort of older adults followed for up to 12 years. RESULTS: There were 184 VTE events that occurred at mean age of 78 years. TagSNPs within four genes encoding FXIII subunit A (F13A), FVII activating protease (HABP2), protease activated receptor-1 (F2R) and the urokinase receptor (PLAUR) showed the strongest evidence for association with VTE, with each gene having a global P-value < 0.05 and at least one tagSNP false discovery rate (FDR) q-value < 0.05. The rs3024409 variant allele of F13A1 was associated with 1.66-fold increased risk of VTE, while the minor alleles of HABP2 rs6585234 and rs3862019, F2R rs253061 and rs153311, and PLAUR rs344782 were each associated with lower risk of VTE (hazard ratios in the range of 0.49-0.66). Consistent with the observed protective association for VTE risk, the HABP2 rs3862019 variant allele was also associated with lower activity levels of coagulation factors FVIII, FIX, FX and plasminogen. We also confirm previously reported associations between common variants of the coagulation FII, FV, FVIII, FXI, alpha-fibrinogen and protein C genes and risk of VTE. CONCLUSIONS: These findings suggest that several novel common coagulation gene variants may be related to risk of VTE in older adults. Further studies in older adults are needed to validate these findings and assess functional molecular mechanisms.
BACKGROUND/ OBJECTIVES: Age-related changes in blood coagulation and fibrinolysis are associated with increased risk of thrombotic events. Inherited deficiencies of coagulation proteins, such as factor V (FV) Leiden and prothrombinG20210A, explain a small fraction of venous thromboembolic disease (VTE). Additional genetic factors are likely to underlie the etiology of VTE, some of which may become manifest at older ages. METHODS: We tested 290 common SNPs within 51 thrombosis and inflammation genes for association with VTE in the Cardiovascular Health Study, a large, prospective cohort of older adults followed for up to 12 years. RESULTS: There were 184 VTE events that occurred at mean age of 78 years. TagSNPs within four genes encoding FXIII subunit A (F13A), FVII activating protease (HABP2), protease activated receptor-1 (F2R) and the urokinase receptor (PLAUR) showed the strongest evidence for association with VTE, with each gene having a global P-value < 0.05 and at least one tagSNP false discovery rate (FDR) q-value < 0.05. The rs3024409 variant allele of F13A1 was associated with 1.66-fold increased risk of VTE, while the minor alleles of HABP2rs6585234 and rs3862019, F2Rrs253061 and rs153311, and PLAURrs344782 were each associated with lower risk of VTE (hazard ratios in the range of 0.49-0.66). Consistent with the observed protective association for VTE risk, the HABP2rs3862019 variant allele was also associated with lower activity levels of coagulation factors FVIII, FIX, FX and plasminogen. We also confirm previously reported associations between common variants of the coagulation FII, FV, FVIII, FXI, alpha-fibrinogen and protein C genes and risk of VTE. CONCLUSIONS: These findings suggest that several novel common coagulation gene variants may be related to risk of VTE in older adults. Further studies in older adults are needed to validate these findings and assess functional molecular mechanisms.
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: Aaron R Folsom; Mary Cushman; Michael Y Tsai; Nena Aleksic; Susan R Heckbert; Lori L Boland; Albert W Tsai; N David Yanez; Wayne D Rosamond Journal: Blood Date: 2002-04-15 Impact factor: 22.113
Authors: Mary Cushman; Aaron R Folsom; Lu Wang; Nena Aleksic; Wayne D Rosamond; Russell P Tracy; Susan R Heckbert Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: Aaron R Folsom; Nena Aleksic; Lu Wang; Mary Cushman; Kenneth K Wu; Richard H White Journal: Arterioscler Thromb Vasc Biol Date: 2002-06-01 Impact factor: 8.311
Authors: Alfonso Buil; David-Alexandre Trégouët; Juan Carlos Souto; Noémie Saut; Marine Germain; Maxime Rotival; Laurence Tiret; Françcois Cambien; Mark Lathrop; Tanja Zeller; Marie-Christine Alessi; Santiago Rodriguez de Cordoba; Thomas Münzel; Philipp Wild; Jordi Fontcuberta; France Gagnon; Joseph Emmerich; Laura Almasy; Stefan Blankenberg; José-Manuel Soria; Pierre-Emmanuel Morange Journal: Blood Date: 2010-03-08 Impact factor: 22.113
Authors: F Yesim K Demirci; Amy S Dressen; Candace M Kammerer; M Michael Barmada; Amy H Kao; Rosalind Ramsey-Goldman; Susan Manzi; M Ilyas Kamboh Journal: J Rheumatol Date: 2011-01-15 Impact factor: 4.666
Authors: N A Zakai; L Lange; W T Longstreth; E S O'Meara; J L Kelley; M Fornage; D Nikerson; M Cushman; A P Reiner Journal: J Thromb Haemost Date: 2011-02 Impact factor: 5.824
Authors: Christina L Wassel; Laura J Rasmussen-Torvik; Peter W Callas; Julie O Denenberg; J Peter Durda; Alexander P Reiner; Nicholas L Smith; Matthew A Allison; Frits R Rosendaal; Michael H Criqui; Mary Cushman Journal: Thromb Res Date: 2015-09-26 Impact factor: 3.944